Cargando…

Hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography

INTRODUCTION: Metabolic syndrome (MS) is characterized by dyslipidemia, central obesity, hypertension and hyperglycemia. However, type 2 diabetes mellitus (T2DM) may or may not be present in metabolic syndrome. MS and T2DM are considered important cardiovascular risk factors, but the role of hypergl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonamichi, Beatriz Dal Santo Francisco, Parente, Erika Bezerra, Campos, Ana Carolina Noronha, Cury, Adriano Namo, Salles, João Eduardo Nunes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302811/
https://www.ncbi.nlm.nih.gov/pubmed/28187174
http://dx.doi.org/10.1371/journal.pone.0171733
_version_ 1782506617561939968
author Bonamichi, Beatriz Dal Santo Francisco
Parente, Erika Bezerra
Campos, Ana Carolina Noronha
Cury, Adriano Namo
Salles, João Eduardo Nunes
author_facet Bonamichi, Beatriz Dal Santo Francisco
Parente, Erika Bezerra
Campos, Ana Carolina Noronha
Cury, Adriano Namo
Salles, João Eduardo Nunes
author_sort Bonamichi, Beatriz Dal Santo Francisco
collection PubMed
description INTRODUCTION: Metabolic syndrome (MS) is characterized by dyslipidemia, central obesity, hypertension and hyperglycemia. However, type 2 diabetes mellitus (T2DM) may or may not be present in metabolic syndrome. MS and T2DM are considered important cardiovascular risk factors, but the role of hyperglycemia in coronary disease is still contested in the literature. Therefore, we decided to evaluate the effect of hyperglycemia on the severity of coronary disease in MS patients, with or without T2DM, submitted to coronary angiography (CA) and intravascular ultrasonography (IVUS). MATERIALS AND METHODS: This is a cross sectional, observational study with 100 MS patients (50% with T2DM), 60% male. All of the patients had been referred for CA procedures. The obstruction was considered severe when stenosis was greater than 70% and moderate if it was between 50–69%. Patients detected with a moderate obstruction by CA were indicated to IVUS. A minimal luminal area of less than 4mm(2) detected by IVUS was also considered severe. IDF criteria were used to define Metabolic Syndrome and T2DM diagnosis was defined according to the American Diabetes Association criteria. Student’s t-test and Pearson Chi-square were used for statistical analysis, considering p < 0.05 statistically significant. RESULTS AND DISCUSSION: The majority of T2DM patients presented severe arterial lesions (74% vs 22%, p<0.001). Using CA procedure, 12% of T2DM had moderate obstructions, compared to 38% of the non-diabetic group (p< 0.05). 8% of patients with moderate lesions by CA were diagnosed with a luminal area less than 4mm(2) using IVUS. This luminal area was significantly smaller in the T2DM group than in the control group (3.8mm(2) ± 2.42. vs 4.6mm(2) ± 2.58, p = 0.03). CONCLUSION: Patients with MS and T2DM submitted to angiography and IVUS, had more severe coronary lesions compared to MS patients without diabetes. This finding suggests that beyond insulin resistance that is present in MS, hyperglycemia may also play a role in the development of atherosclerotic disease. IVUS was useful for diagnosing 8% of severe cases initially considered to be moderate obstructions when using just CA in this scenario.
format Online
Article
Text
id pubmed-5302811
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53028112017-02-28 Hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography Bonamichi, Beatriz Dal Santo Francisco Parente, Erika Bezerra Campos, Ana Carolina Noronha Cury, Adriano Namo Salles, João Eduardo Nunes PLoS One Research Article INTRODUCTION: Metabolic syndrome (MS) is characterized by dyslipidemia, central obesity, hypertension and hyperglycemia. However, type 2 diabetes mellitus (T2DM) may or may not be present in metabolic syndrome. MS and T2DM are considered important cardiovascular risk factors, but the role of hyperglycemia in coronary disease is still contested in the literature. Therefore, we decided to evaluate the effect of hyperglycemia on the severity of coronary disease in MS patients, with or without T2DM, submitted to coronary angiography (CA) and intravascular ultrasonography (IVUS). MATERIALS AND METHODS: This is a cross sectional, observational study with 100 MS patients (50% with T2DM), 60% male. All of the patients had been referred for CA procedures. The obstruction was considered severe when stenosis was greater than 70% and moderate if it was between 50–69%. Patients detected with a moderate obstruction by CA were indicated to IVUS. A minimal luminal area of less than 4mm(2) detected by IVUS was also considered severe. IDF criteria were used to define Metabolic Syndrome and T2DM diagnosis was defined according to the American Diabetes Association criteria. Student’s t-test and Pearson Chi-square were used for statistical analysis, considering p < 0.05 statistically significant. RESULTS AND DISCUSSION: The majority of T2DM patients presented severe arterial lesions (74% vs 22%, p<0.001). Using CA procedure, 12% of T2DM had moderate obstructions, compared to 38% of the non-diabetic group (p< 0.05). 8% of patients with moderate lesions by CA were diagnosed with a luminal area less than 4mm(2) using IVUS. This luminal area was significantly smaller in the T2DM group than in the control group (3.8mm(2) ± 2.42. vs 4.6mm(2) ± 2.58, p = 0.03). CONCLUSION: Patients with MS and T2DM submitted to angiography and IVUS, had more severe coronary lesions compared to MS patients without diabetes. This finding suggests that beyond insulin resistance that is present in MS, hyperglycemia may also play a role in the development of atherosclerotic disease. IVUS was useful for diagnosing 8% of severe cases initially considered to be moderate obstructions when using just CA in this scenario. Public Library of Science 2017-02-10 /pmc/articles/PMC5302811/ /pubmed/28187174 http://dx.doi.org/10.1371/journal.pone.0171733 Text en © 2017 Bonamichi et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Bonamichi, Beatriz Dal Santo Francisco
Parente, Erika Bezerra
Campos, Ana Carolina Noronha
Cury, Adriano Namo
Salles, João Eduardo Nunes
Hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography
title Hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography
title_full Hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography
title_fullStr Hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography
title_full_unstemmed Hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography
title_short Hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography
title_sort hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302811/
https://www.ncbi.nlm.nih.gov/pubmed/28187174
http://dx.doi.org/10.1371/journal.pone.0171733
work_keys_str_mv AT bonamichibeatrizdalsantofrancisco hyperglycemiaeffectoncoronarydiseaseinpatientswithmetabolicsyndromeevaluatedbyintracoronaryultrasonography
AT parenteerikabezerra hyperglycemiaeffectoncoronarydiseaseinpatientswithmetabolicsyndromeevaluatedbyintracoronaryultrasonography
AT camposanacarolinanoronha hyperglycemiaeffectoncoronarydiseaseinpatientswithmetabolicsyndromeevaluatedbyintracoronaryultrasonography
AT curyadrianonamo hyperglycemiaeffectoncoronarydiseaseinpatientswithmetabolicsyndromeevaluatedbyintracoronaryultrasonography
AT sallesjoaoeduardonunes hyperglycemiaeffectoncoronarydiseaseinpatientswithmetabolicsyndromeevaluatedbyintracoronaryultrasonography